{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/herpes-simplex-oral/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"0b1ea486-a30d-554a-87c3-68b2a981d26d","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 9567188f-2fad-4f17-b9c8-7f09cdce45f5 --><h2>Changes</h2><!-- end field 9567188f-2fad-4f17-b9c8-7f09cdce45f5 -->","summary":null,"htmlStringContent":"<!-- begin item 25ec0d2a-76d2-4775-9eba-a0248359131d --><!-- begin field 0b31378e-934c-49c8-aaeb-bc27fb9fff80 --><p><strong>September to October 2016 </strong>— reviewed. A literature search was conducted in September 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials since the last revision of this topic. The recommendations on primary care management and referral have been updated in line with current evidence. The topic has also undergone minor restructuring.</p><!-- end field 0b31378e-934c-49c8-aaeb-bc27fb9fff80 --><!-- end item 25ec0d2a-76d2-4775-9eba-a0248359131d -->","topic":{"id":"401dad14-da6a-5b54-bb3d-2cfea5661d4b","topicId":"5f875f0c-db78-44fb-b672-bd54c9216205","topicName":"Herpes simplex - oral","slug":"herpes-simplex-oral","lastRevised":"Last revised in October 2016","chapters":[{"id":"2106bbf3-357c-5e99-8faf-4898c1ca935e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"83c52d0f-97ef-5a31-8ff4-41d30aff63ad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"88707caf-63e9-5b1e-bd0d-adca6b1e4d1b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0b1ea486-a30d-554a-87c3-68b2a981d26d","slug":"changes","fullItemName":"Changes"},{"id":"96fd5acc-0417-54f9-8185-fd7234a33908","slug":"update","fullItemName":"Update"}]},{"id":"56d4e2ce-1a2c-5bbf-9a02-d7ec1fe80537","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"abbdfc66-bff5-502d-ad7d-32c81000d0f2","slug":"goals","fullItemName":"Goals"},{"id":"b3a9824a-ae33-5fa9-81e7-a932b005c125","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f2bb54c7-b5b0-5b30-a704-921dce3f32c9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d3f7ec4d-ecc0-5956-b6b6-22c492e1122f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9944dadf-7acf-5f24-8f20-c050c044edba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"425c65b2-de3b-5863-b73c-72199baee6f1","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"5749e0ab-cd7c-5a50-bc2c-ef816e9599c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1d630313-1e41-59ae-8ae9-5cd26302276f","slug":"definition","fullItemName":"Definition"},{"id":"31a0a436-27cb-58e7-949b-76fb6dbd9c54","slug":"transmission","fullItemName":"Transmission"},{"id":"98ffdaac-76d5-54c1-93f5-7dd4a2f9148b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bf160e19-7acf-5ed0-9c7a-be8eeb5b5d1c","slug":"complications","fullItemName":"Complications"},{"id":"739ee047-f37b-56ca-ae40-7c3875158ee6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"bc2ab338-32ce-50dc-8b2b-3546b85d2d9f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"78e575da-c305-5bf9-b61a-f062ae2c4eb5","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e37bcee1-69de-5e61-9294-81ff5642fa57","slug":"assessment","fullItemName":"Assessment"},{"id":"ed37f634-077a-5cf4-880d-5d2e9e5e5d9c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ca77797d-b745-54df-ae5b-ca78f5b20941","fullItemName":"Management","slug":"management","subChapters":[{"id":"3270af1a-6907-5c03-9ffb-c4d827c56103","slug":"herpes-labialis-gingivostomatitis","fullItemName":"Scenario: Herpes labialis and gingivostomatitis"}]},{"id":"059e9ce0-0874-50ea-b177-6ae9c92398c4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8416d8f1-2061-51a1-b6ab-29d314b7738e","slug":"analgesia","fullItemName":"Analgesia"},{"id":"eeff86e7-c71a-5781-a929-0698c0bcfc16","slug":"oral-antiviral-drugs","fullItemName":"Oral antiviral drugs"}]},{"id":"3a06d913-863d-5a7d-a6ce-6f327e1db685","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"981bfc0e-bf2d-528d-a298-5ed824004d46","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d4db274b-f8f9-559e-8053-48f1712ad1f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1ee8a0ab-5883-561f-9aed-2524df466dfb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1c48988f-4b5b-512c-90dc-8f7341fd9a0f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e1757009-f8a2-561e-9c49-0048e0c195b9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9fbce5d9-f27e-5f7c-8744-4b00ad58e71d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d5966d8c-2014-541a-bd9b-fbab33577d44","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"88707caf-63e9-5b1e-bd0d-adca6b1e4d1b","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6b17ee63-5f0d-5161-9996-ff23021a853e","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 23ea0348-0f8f-4c5c-a92e-ad970671da5e --><h3>Previous changes</h3><!-- end field 23ea0348-0f8f-4c5c-a92e-ad970671da5e -->","summary":null,"htmlStringContent":"<!-- begin item 3ccd8951-6857-4cb1-9675-2aae00e9bbe5 --><!-- begin field 979baab4-2b95-4486-8bd3-f49d81356509 --><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>August 2012 </strong>— reviewed. A literature search was conducted in August 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) document <em>Press release: more exact paracetamol dosing for children to be introduced</em> (2011). Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>April 2009 </strong>— minor update. Topical products containing choline salicylate (such as Bonjela<sup>®</sup>) are no longer licensed for use in children under 16 years of age because of the theoretical risk of Reye's syndrome if they are overused. The prescriptions have been updated accordingly. Issued in May 2009.</p><p><strong>April 2008 </strong>— minor update to text following late comments from an external reviewer.</p><p><strong>September to December 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>October 2006 </strong>— minor update. Analgesia prescriptions updated because new doses of ibuprofen for children are recommend by the British National Formulary. Issued in October 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>July 2005 </strong>— updated to incorporate the document <em>Referral guidelines for suspected cancer</em> (2005) published by the National Institute for Health and Clinical Excellence (NICE). Issued in July 2005.</p><p><strong>June 2004 </strong>— reviewed. Validated in September 2004 and issued in November 2004.</p><p><strong>January 2002 </strong>— rewritten. Validated in March 2002 and issued in April 2002.</p><p><strong>August 1998 </strong>— written, replacing guidance called <em>Herpes simplex gingivostomatitis</em>.</p><!-- end field 979baab4-2b95-4486-8bd3-f49d81356509 --><!-- end item 3ccd8951-6857-4cb1-9675-2aae00e9bbe5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}